Conflict of Interest as seen from a researcher's perspective

Science and Engineering Ethics

Volumn 8, Issue 3, 2002, Pages 337-342

  Schieppati, Arrigo ^a,b   Perico, Norberto ^a   Remuzzia, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Academic research; Clinical trial design; Conflict of interest; Drug development and research

Indexed keywords

BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMAN; PERSONNEL; RESEARCH ETHICS; REVIEW; STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS, RESEARCH; HUMANS; RESEARCH PERSONNEL;

EID: 0036654662     PISSN: 13533452     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11948-002-0053-y     Document Type: Article

References (22)

1. Pharma2005: An industrial revolution in R&D. New York, NY: PriceWaterhouseCoopers; 1998. Available at http://www.pwcconsulting.com/us/pwccons.nsf/viewwebpages/PharmaPubSeries. Accessibility verified May 2002.
2. The new era of lifestyle drugs. BusinessWeek May 11, 1998. Available at http://www.businessweek.com/1998/19/topstory.htm. Accessibility verified May 2002.
3. Garattini S. (1997) Are me-too drugs justified? J Nephrol. 10: 283-94.
4. Montaner J.S., O'Shaughnessy M.V., Schechter M.T. (2001) Industry-sponsored clinical research: a double-edged sword, Lancet 358: 1893-5.
5. Rochon P.A., Gurwitz J.H, Simms R.W., et al. (1994) A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 154: 157-63.
6. Margreiter R. (2002) Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359: 741-6.
7. Perna A., Gotti E., de Bernardis E., Perico N., Remuzzi G. (1996) A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol 7: 786-91.
8. Davidoff F., DeAngelis C.D., Drazen J.M., et al. (2001) Sponsorship, authorship and accountability. Lancet 358: 854-6.
9. Parving H-H, Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Amer P. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-78.
10. Brenner B.M., Cooper M.E., de Zeeuw D., et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-69.
11. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-60.
12. Hostetter T.H. (2001) revention of End-Stage Renal Disease Due to Type 2 Diabetes. N Engl J Med 345: 910-12.
13. Kurtzman N.A. (2001) Drug companies should not have the final say in the design of clinical trials. Am J Kidney Dis 38: 1113-4.
14. Choudhry N.K., Stelfox H.T., Detsky A.S. (2002) Relationship between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287: 612-17.
15. About the 1999 WHO/ISH guidelines for the management of hypertension. Available at http://www.uib.no/isf/letter Accessibility verified May 2002.
16. Hansson L., Zanchetti A., George Carruthers S., et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755-62.
17. Quick J. (2001) Maintaining the integrity of the clinical evidence base. Bulletin of the WHO 79: 1093.
18. Bodenheimer T. (2000) Uneasy alliance. N Engl J Med 342: 1539-44.
19. Angell M. (2000) Is academic medicine for sale? N Engl J Med 342: 1516.
20. Retting R.A. (2000) The industrialization of clinical research. Health Affairs 19: 129-46.
21. Morin K., Rakatanski H., Riddick F.A., et al.(2002) Managing conflict of interest in the conduct of clinical trials. JAMA 287: 78-84.
22. Schieppati A., Garattini S., Remuzzi G. (2001) Modulating the profit motive to meet needs of the less-developed world. Lancet. 358: 1638-41.